We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
Vienna, Austria

ESTRO 2023

Session

Saturday
May 13
10:30 - 11:30
Business Suite 1-2
Lung 1
Jose Belderbos, The Netherlands
Poster Discussions are presented in one of the sessions scheduled at the two poster discussion theatres. Each author will present a digital poster orally for 2 minutes, followed by 2 minutes for discussion. Sessions will not be recorded.
1300
Poster Discussion
Clinical
Radiation induced lymphopenia, its effect on pathologic regression and prognosis in LA lung cancer
Sarit Appel, Israel
PD-0153
Dosimetric analysis of bronchial tree to assess toxicity-risk in SBRT of ultracentral lung tumors
Maiwand Ahmadsei, Switzerland
PD-0154
Health-related quality of life in the randomised ARTFORCE PET-Boost trial in locally-advanced NSCLC
Saskia Cooke, The Netherlands
PD-0155
Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer
Jörg Andreas Müller, Germany
PD-0156
No changes in pulmonary function by spirometry after Stereotactic Body Radiotherapy in lung lesions
Abraham Andre Arturo Geng Cahuayme, Spain
PD-0157
Cardiac dose and survival in stereotactic lung radiotherapy: results of multi-centre SSBROC trial
Vicky Chin, Australia
PD-0158
Association of Statin Intensity With Cardiac Events and Mortality After Radiotherapy for NSCLC
Gerard Walls, United Kingdom
PD-0159
A clinical evaluation of automatic open-source segmentation algorithm for lung cancer patients
Agon Olloni , Denmark
PD-0160
Actual radiotherapy utilisation for lung cancer in Europe: a systematic literature review
Josep M Borras, Spain
PD-0161
Thymic epithelial tumour radiotherapy: A survey of current UK clinical practice
Stephen Robinson, United Kingdom
PD-0162
Effects of radiotherapy interruptions in lung cancer disease control: a multicenter study
Elias Gomis Selles, Spain
PD-0151
Radiation-induced lymphopenia risk model predicts durvalumab benefit in non-small cell lung cancer.
Peter van Rossum, The Netherlands
PD-0152